Targeting glycerophospholipid biosynthesis overcomes chemoresistance driven by SLFN11 loss in Ewing sarcoma

Published: 13 June 2025| Version 1 | DOI: 10.17632/449982vf6p.1
Contributors:
Kasturee Chakraborty, Ritambhar Burman, Saharsh Satheesh, Matthew Kieffer, Chandni Karuhatty, Zuo-Fei Yuan, Haiyan Tan, Ankhbayar Lkhagva, Anthony A High, Xusheng Wang, Alaa Refaat, Nathaniel R Twarog, Weixing Zhang, Yaxu Wang, Yiping Fan, M Madan Babu, Anang Shelat, Elizabeth Stewart, Michael A Dyer, Puneet Bagga

Description

In Ewing sarcoma, high SLFN11 expression mediates initial sensitivity to DNA-damaging agents. However, relapse poses a major barrier due to heterogeneous expression or loss of SLFN11 causing therapeutic resistance. Although SLFN11 is established as a predictive biomarker, the mechanisms by which its loss promotes chemoresistance remain poorly understood, creating a critical gap that limits the development of effective treatments. This study shows that loss of SLFN11 induces a distinct metabolic reprogramming in Ewing sarcoma cells. Using integrated transcriptomic, metabolomic, and stable isotope tracing analyses, we identify downregulation of mitochondrial GPD2 and increased glycerophospholipid biosynthesis associated with SLFN11 loss. This study further demonstrates that targeting lipid biosynthesis impairs the viability of SLFN11-deficient cells. Notably, these findings are supported by in vivo data from xenograft models, which reveal elevated choline-derived phospholipid synthesis, suggesting metabolic adaptation in the tumor microenvironment.

Files

Categories

Lipid Biosynthesis, Drug Resistance, Ewing Sarcoma, Cancer Metabolism

Funders

Licence